tirzepatide 日本 Rising Use of Diabetes Drugs for Weight Loss Raises Health Concerns 週1回投与のデュアルGIP/GLP-1受容体作動薬「Tirzepatide」の第3相試験 2型糖尿病患者のHbA1cおよび体重を有意に減少 | 糖尿病リソースガイド

In a clinical trial examining dulaglutide as a varenicline adjunct, the GLP-1 component successfully reduced post-cessation weight gain when compared to placebo plus varenicline, even though abstinence rates did not improve

The British Journal of Nutrition

Patients with proliferative retinopathy or maculopathy resulting in active treatment were excluded from the PIONEER 6 CVOT, in which no apparent imbalance was observed between oral semaglutide and placebo in the AE reporting of diabetic retinopathy over 16 months (87)

10.1007/s00125-016-4157-3 151 WangG.LiQ.ChenD.WuB.WuY.TongW.et al (2019)

While this test does not measure thyroid-specific variants, it shows how your genetic architecture relates to glucose metabolism, appetite regulation, and inflammatory pathways that can secondarily affect thyroid health

Second Nature remains an NHS-commissioned provider for weight management and diabetes prevention